Serving Overlooked PatientsSM
Azurity Pharmaceuticals is a privately held company committed to delivering innovative, high-quality medicines for overlooked patients. Azurity’s global footprint is over 50 countries, with a diversified portfolio of 50+ medicines spanning 10 dosage forms and 10 key therapeutic areas. Powered by its Next-Gen Commercial Model, Azurity leverages data, analytics, and AI-driven digital tools to enhance market reach and stakeholder engagement. Our medicines have benefited millions of people.
PRODUCT ANNOUNCEMENT
NOW AVAILABLE

Click for Full Prescribing Information,
including Indication, BOXED WARNING, and Important Safety Information.
PRODUCT ANNOUNCEMENT

Click for Full Prescribing Information, including Indication and Additional Safety Information.
PRODUCT ANNOUNCEMENT
NOW AVAILABLE

Click for Full Prescribing Information, including Indication, BOXED WARNING, and Important Safety Information.
PRODUCT ANNOUNCEMENT

Click for Full Prescribing Information, including Indication and Additional Safety Information.
OUR PRODUCTS
Azurity offers an ever expanding portfolio of products targeting key therapeutic areas.
News & Events
Azurity Announces Plans to Commercialize D-PLEX100 in the U.S. and Canada through Exclusive Partnership with PolyPid
Woburn, MA—July 21, 2026—Azurity Pharmaceuticals, a privately held specialty pharmaceutical company, today announced plans to commercialize D-PLEX100 upon approval in the United States and Canada for the prevention of abdominal colorectal surgical site infections (“SSIs”) in partnership with PolyPid Ltd. (“PolyPid”), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, who will manufacture and supply D-PLEX100
Azurity Pharmaceuticals Expands Portfolio with CONTRAVE® and Related Assets
WOBURN, Mass. — June 30, 2026 — Azurity Pharmaceuticals, a global pharmaceutical company dedicated to redefining medicine for the real world, today announced the expansion of its portfolio through the acquisition of CONTRAVE® and related assets, expanding the company’s presence in obesity and chronic weight management.